Bargieri Daniel Y, Soares Irene S, Costa Fabio T M, Braga Catarina J, Ferreira Luis C S, Rodrigues Mauricio M
Centro de Terapia Celular e Molecular (CTCMol), Universidade Federal de São Paulo, Escola Paulista de Medicina, Rua Mirassol 207, São Paulo 04044-010, SP, Brazil.
J Parasitol Res. 2011;2011:965369. doi: 10.1155/2011/965369. Epub 2011 Mar 14.
In the past 25 years, the development of an effective malaria vaccine has become one of the biggest riddles in the biomedical sciences. Experimental data using animal infection models demonstrated that it is possible to induce protective immunity against different stages of malaria parasites. Nonetheless, the vast body of knowledge has generated disappointments when submitted to clinical conditions and presently a single antigen formulation has progressed to the point where it may be translated into a human vaccine. In parallel, new means to increase the protective effects of antigens in general have been pursued and depicted, such as the use of bacterial flagellins as carriers/adjuvants. Flagellins activate pathways in the innate immune system of both mice and humans. The recent report of the first Phase I clinical trial of a vaccine containing a Salmonella flagellin as carrier/adjuvant may fuel the use of these proteins in vaccine formulations. Herein, we review the studies on the use of recombinant flagellins as vaccine adjuvants with malarial antigens in the light of the current state of the art of malaria vaccine development. The available information indicates that bacterial flagellins should be seriously considered for malaria vaccine formulations to the development of effective human vaccines.
在过去25年里，研发一种有效的疟疾疫苗已成为生物医学领域最大的谜题之一。利用动物感染模型获得的实验数据表明，诱导针对疟原虫不同阶段的保护性免疫是有可能的。然而，大量知识在应用于临床时却令人失望，目前仅有单一抗原制剂进展到可能转化为人类疫苗的阶段。与此同时，人们一直在探索并描述提高抗原总体保护效果的新方法，比如使用细菌鞭毛蛋白作为载体/佐剂。鞭毛蛋白可激活小鼠和人类先天免疫系统中的通路。近期关于一种含有沙门氏菌鞭毛蛋白作为载体/佐剂的疫苗的首次I期临床试验报告，可能会推动这些蛋白质在疫苗制剂中的应用。在此，我们根据疟疾疫苗研发的当前技术水平，综述关于使用重组鞭毛蛋白作为疟疾抗原疫苗佐剂的研究。现有信息表明，在开发有效的人类疫苗时，细菌鞭毛蛋白应被认真考虑用于疟疾疫苗制剂。
